What is the Origin of Peptide CJC-1295?

CJC-1295 was developed in the early 2000s as part of research into sustained-release therapeutic agents for GH deficiency, aiming to overcome the short half-life of native GHRH. The DAC modification represents a pharmaceutical innovation to enhance pharmacokinetic properties.

What is the Mechanism of Peptide CJC-1295?

By binding to the GHRH receptor in the anterior pituitary, CJC-1295 mimics the action of endogenous GHRH, promoting the synthesis and release of GH. The extended half-life, due to its conjugation with serum albumin, ensures a prolonged and consistent stimulation of the pituitary, leading to sustained elevation of GH and its downstream mediator, Insulin-like Growth Factor 1 (IGF-1), without the supraphysiological spikes associated with exogenous GH administration.

Peptide CJC-1295 ∞ Area

Peptide CJC-1295

Meaning

Peptide CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) classified as a Growth Hormone Releasing Hormone Analog (GHRH-RA), which functions as a potent secretagogue. Its primary clinical utility lies in its ability to stimulate the pituitary gland to secrete endogenous growth hormone (GH) in a pulsatile, physiological manner. This peptide is characterized by a Drug Affinity Complex (DAC) modification, which significantly extends its half-life, allowing for less frequent dosing while maintaining stable, therapeutic GH and IGF-1 levels.